Merck (MRK -1.75%) recently announced positive Phase 1b clinical study results for its experimental Alzheimer's disease drug MK-8931. This compound belongs to a broader class of experimental Alzheimer's treatments called BACE inhibitors, and AstraZeneca (AZN -2.36%) and Eli Lilly (LLY 0.16%) have also explored drugs in this class. In the following video, health-care analyst Max Macaluso discusses the latest results, why shares of Merck didn't move significantly on the news, and also takes a look at the broader BACE inhibitor space.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Merck is hoping for more positive results from its experimental Alzheimer's disease drug.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$80.94
(-1.75%)
$-1.45
AstraZeneca Plc
AZN
$69.45
(-2.36%)
$-1.68
Eli Lilly
LLY
$780.55
(0.16%)
$1.27
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Beaten-Down Stocks With Massive Upside Potential
Why Did Oscar Health Crash on Wednesday and Is This a Huge Buying Opportunity?
Is Pfizer Stock a Yield Trap?
3 Things You Need to Know If You Buy Walgreens Today
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.